Asia-Pacific Cancer Monoclonal Antibodies Market By Application (Liver, Breast, Blood, Brain, Hodgkin’s And Non-Hodgkin’s Lymphoma, Colorectal, Leukaemia And Others) By Type (murine Antibodies, Chimeric And Humanised Antibodies And Fully Humanized Antibodies) By Conjugated Cancer Therapies And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

Asia-Pacific Cancer Monoclonal Antibodies Market By Application (Liver, Breast, Blood, Brain, Hodgkin’s And Non-Hodgkin’s Lymphoma, Colorectal, Leukaemia And Others) By Type (murine Antibodies, Chimeric And Humanised Antibodies And Fully Humanized Antibodies) By Conjugated Cancer Therapies And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018–2023)

ID: 188 | Pages: 145 | April 2018 | Region: Asia Pacific


Overview of the Market:
Cancer is the leading cause of death across the globe currently. It starts from a single cell in the body genetically transforming a normal cell to a tumour and is eventually spread to other cells. Typically, drugs and chemotherapy are used as a treatment to cure cancer. The adverse side effects that comes with them has made the pharmaceutical companies to concentrate on monoclonal antibodies.

Asia-Pacific Monoclonal Antibodies Market is currently valued at USD 5.94 billion in 2018 and is forecasted to be a USD 10.95 Billion market by 2023 with a tremendous growth rate of 13%.

Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat the disease. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to cancer. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the cancerous cells not effecting the normal ones.

With the increase in the cases of cancer in the recent past, the pharmaceutical companies has started investing aggressively in monoclonal antibodies. The primary drivers for the market include increased investment in R&D for genomic studies, specificity to target only the cancer cell by monoclonal antibodies and technological evolvement in genetic sequencing and target gene selection. However, high costs of development, longer durations required for clinical trials and research & development of antibodies are a few factors to overcome in order for the market to evolve.

Geographical Analysis: 
The Asia-Pacific Monoclonal Antibodies Market are divided based on its application as Breast, liver, Brain, Blood, colorectal, leukaemia, Hodgkins & Non-Hodgkins and others. The market is further analysed on the basis of type as fully humanized antibodies, murine antibodies and chimeric & humanised antibodies. The market based on Conjugated Cancer therapies is segmented as Immunocytokines, ADEPT, Radioimmunotherapy and Immunoliposome. The market based on the geography of Asia-Pacific is segmented as China, India, Japan, South Korea and others.

Key Players in this Market: 
The key players of the market are Amgen, Bristol Myers Squibb, Eli Lilly, Roche, Immunogen, Novartis, Glaxosmithkline, Genmab, Seattle Genetics and Spectrum Pharaceuticals.

 

  1. Introduction

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

  1. Research Methodology

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

  1. Overview

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

  1. Market Segmentation

                5.1 By Application           

                                5.1.1 Liver

                                5.1.2 Breast

                                5.1.3 Brain

                                5.1.4 Blood

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma

                                5.1.6 Colorectal

                                5.1.7 Leukaemia

                                5.1.8 Others

                5.2 By Type        

                                5.2.1 Murine Antibodies

                                5.2.2 Chimeric and Humanised Antibodies

                                5.2.3 Fully Humanized Antibodies

                5.3 Conjugate Cancer Therapies               

                                5.3.1 Immunoliposome

                                5.3.2 Radioimmunotherapy

                                5.3.3 ADEPT

                                5.3.4 Immunocytokines

                                5.3.5 Others

  1. Geographical Analysis

                6.1 Introduction               

                6.2 China             

                6.3 India              

                6.4 Japan            

                6.5 South Korea               

  1. Strategic Analysis

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

  1. Market Leaders' Analysis

                8.1 Roche

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Amgen

                8.3 Genmab

                8.4 Glaxosmithkline

                8.5 Bristol Meyer Squibb

                8.6 Eli Lilly

                8.7 Immunogen

                8.8 Novartis

                8.9 Seattle Genetics

                8.10 Spectrum Pharmaceuticals

  1. Competitive Landscape

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

  1. Expert Opinions

                10.1 Market Outlook     

                10.2 Investment Opportunities 

     Appendix                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Cancer Monoclonal Antibodies Market By Region, From 2018-2023 ( USD Million )
  2. Asia-Pacific Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  3. Asia-Pacific Liver Market By Region, From 2018-2023 ( USD Million )
  4. Asia-Pacific Breast Market By Region, From 2018-2023 ( USD Million )
  5. Asia-Pacific Brain Market By Region, From 2018-2023 ( USD Million )
  6. Asia-Pacific Blood Market By Region, From 2018-2023 ( USD Million )
  7. Asia-Pacific Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2018-2023 ( USD Million )
  8. Asia-Pacific Colorectal Market By Region, From 2018-2023 ( USD Million )
  9. Asia-Pacific Leukaemia Market By Region, From 2018-2023 ( USD Million )
  10. Asia-Pacific Others Market By Region, From 2018-2023 ( USD Million )
  11. Asia-Pacific Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  12. Asia-Pacific Murine Antibodies Market By Region, From 2018-2023 ( USD Million )
  13. Asia-Pacific Chimeric and Humanised Antibodies Market By Region, From 2018-2023 ( USD Million )
  14. Asia-Pacific Fully Humanized Antibodies Market By Region, From 2018-2023 ( USD Million )
  15. Asia-Pacific Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  16. Asia-Pacific Immunoliposome Market By Region, From 2018-2023 ( USD Million )
  17. Asia-Pacific Radioimmunotherapy Market By Region, From 2018-2023 ( USD Million )
  18. Asia-Pacific ADEPT Market By Region, From 2018-2023 ( USD Million )
  19. Asia-Pacific Immunocytokines Market By Region, From 2018-2023 ( USD Million )
  20. Asia-Pacific Others Market By Region, From 2018-2023 ( USD Million )
  21. Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  22. Liver Market By Region, From 2018-2023 ( USD Million )
  23. Breast Market By Region, From 2018-2023 ( USD Million )
  24. Brain Market By Region, From 2018-2023 ( USD Million )
  25. Blood Market By Region, From 2018-2023 ( USD Million )
  26. Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2018-2023 ( USD Million )
  27. Colorectal Market By Region, From 2018-2023 ( USD Million )
  28. Leukaemia Market By Region, From 2018-2023 ( USD Million )
  29. Others Market By Region, From 2018-2023 ( USD Million )
  30. China Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  31. China Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  32. China Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  33. India Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  34. India Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  35. India Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  36. Japan Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  37. Japan Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  38. Japan Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  39. South Korea Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  40. South Korea Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  41. South Korea Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
Middle East And Africa Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth...
Asia Pacific Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, A...
Europe Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Fo...
North America Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, ...
Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts ...
Middle East And Africa Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) A...
Latin America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Asia Pacific Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Regi...
Europe Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - I...
North America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - Industry...
Pharmaceutical Gelatin Market By Function (stabilizers, Thickeners, Gelling Agents And Others) , By Source( Pig Skin, Bovine Hides, Bones And Others), By Application ( Hard Capsules, Soft Capsules, Microencapsulatio...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.